Overview
On 19 November 2007, orphan designation (EU/3/07/494) was granted by the European Commission to Celgene Europe Limited, UK, for lenalidomide for the treatment of chronic lymphocytic leukaemia.
The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in July 2018.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.
Key facts
Active substance |
lenalidomide
|
Intended use |
Treatment of chronic lymphocytic leukaemia
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/07/494
|
Date of designation |
19/11/2007
|
Sponsor |
Celgene Europe B.V.
Winthontlaan 6 N 3526 KV Utrecht Tel. +31 (0)30 284 4547 E-mail: medinfo.intl@celgene.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: